Biogen unblurs life with Friedreich ataxia in patient-centered Skyclarys campaign

Biogen Skyclarys campaign
The recently launched campaign debuted at the International Congress for Ataxia Research (ICAR) earlier this month. (Biogen)

Biogen is visualizing life amid disease progression in its newest Friedreich ataxia (FA)-focused campaign, reminding prospective users of its oral medicine Skyclarys that while “life moves fast, progression doesn’t have to.”

To honor that premise, a series of campaign images show people with FA doing various activities in different settings, each seen as a still focal point in the photo while the people surrounding them are blurred. 

One image depicts an FA patient in the gym, holding a weight ball as others work out around him in blurry motions. Another focuses on a boy playing video games, sitting in the center of the couch as his friends excitedly react out-of-focus beside him. 

Yet another photo depicts a woman with FA browsing items at an antique store. In this one, her caretaker beside her is also seen unblurred, standing out compared to the in-motion people in the background. A similar composition plays out in one of the campaign images in which two women, one with FA, enjoy a meal at a food truck amid a busy background of blurred people. 

The company centered the campaign around the voices and experiences of real patients on Skyclarys, including their care partners as well, as those relationships are an “incredibly important” part of FA patients’ journeys, Biogen’s head of ataxia franchise, Kara Bogart McManus, said in a recent interview. 

The project was meant to move the conversation beyond disease progression itself to the special moments, passions and milestones that patients say “make progression meaningful for them,” McManus explained. Upon first getting diagnosed with FA, patients may feel inundated with information or fearful that they won’t be able to keep pace with the quickly moving world around them. 

Biogen’s new campaign visuals “zoom in and focus on what truly matters” to patients in their FA journey, she said. 

“The work really celebrates some of the everyday activities and goals that people with FA want to continue to do, but it also encourages us all to focus on what matters,” McManus said. 

Slowing FA progression has long been a part of Biogen’s Skyclarys messaging and is central to how the 2023-approved drug works to treat the disease. With “Life moves fast,” the company highlights “every moment that is worth slowing progression for,” McManus said. 

People with FA directly informed the visual appearance of the campaign, ensuring it reflected their personal interests and hobbies to portray who they are outside of their disease. For example, the patient featured exercising in the campaign loves being at the gym, McManus pointed out. His feature at the gym also speaks to the importance of exercising for those with FA, something voiced by both the scientific and the patient communities. 

The recently launched campaign debuted at the International Congress for Ataxia Research (ICAR) earlier this month and will continue to roll out via field resources and online. At ICAR, the company’s booth was decked out in a fishing theme, complete with fishing rods and a stream to tie-in to the feature campaign image, which centered on a patient who loves to fish.  

FA is a genetic degenerative neuromuscular disorder that impacts some 5,000 people in the U.S., according to Biogen. However, only about 4,000 people in that group have been diagnosed, with misdiagnoses remaining prevalent for the disease, McManus told Fierce. To bring accurate diagnoses up to speed, Biogen is focusing on educating physicians and those who treat ataxias on FA specifically, as well as the genetic tests needed to diagnose. The company sponsors a genetic testing program that allows eligible patients to qualify for no-cost testing. 

Biogen brought Skyclarys into the fold through its $7.3 billion Reata Pharmaceuticals deal in 2023. Since then, the company’s Skyclarys marketing has garnered international recognition, with its humorous social media series “Friedreich’s Back” coming away from the Cannes Lions International Festival of Creativity with a Gold Pharma Lions award in 2025. The 21Grams-partnered project also leaned heavily on input from the FA community and work with patient advocates.  

Last year, the drug brought in annual worldwide sales of $520 million, bringing the company’s total rare disease revenue to $2.15 billion.